Technology
Health
Pharmaceutical

Neos Therapeutics

$3.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.15 (5.24%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell NEOS and other stocks, options, ETFs, and crypto commission-free!

About

Neos Therapeutics, Inc. Common Stock, also called Neos Therapeutics, is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Read More Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.

Employees
215
Headquarters
Grand Prairie, Texas
Founded
1994
Market Cap
142.07M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
362.76K
High Today
$3.13
Low Today
$2.85
Open Price
$2.90
Volume
724.27K
52 Week High
$8.70
52 Week Low
$1.40

Collections

Technology
Health
Pharmaceutical
Therapy
Manufacturing
2015 IPO
US
North America

News

Simply Wall StMar 25

What Kind Of Investor Owns Most Of Neos Therapeutics, Inc. (NASDAQ:NEOS)?

A look at the shareholders of Neos Therapeutics, Inc. (NASDAQ:NEOS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. So it’s nice to see some insider ownership, because it may suggest that management is owner-oriented. Neos Therapeutics is ...

31
Guru FocusMar 18

Neos Therapeutics Inc (NEOS) Files 10-K for the Fiscal Year Ended on December 31, 2018

Neos Therapeutics Inc (NASDAQ:NEOS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies.

83
Seeking AlphaMar 14

Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q4 2018 Results - Earnings Call Transcript

Neos Therapeutics, Inc. (NASDAQ:NEOS) Q4 2018 Results Conference Call March 14, 2019 9:30 AM ET Company Participants Richard Eisenstadt - CFO Jerry McLaughlin - CEO Conference Call Participants Louise Chen - Cantor Fitzgerald Jason Butler - JMP Securities Bill Maughan - Cowen and Company Gary Nachman - BMO Capital Markets Jacob Hughes - Wells Fargo Operator Good morning. And welcome to the Neos Therapeutics' Fourth Quarter and Full Year 2018 Financial Results Conference Call. Today's call is bein...

110

Earnings

-$0.83
-$0.63
-$0.43
-$0.23
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.28 per share
Actual
-$0.23 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.